Statistics from Altmetric.com
We would like to thank Zeng et al1 for their comments on the Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES)2 and the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT)3 and its long-term follow-up.4
In MOVES,2 glucosamine plus chondroitin sulfate was non-inferior to celecoxib (primary outcome: mean decrease in Western Ontario and McMaster (WOMAC) pain score) in 606 patients with knee osteoarthritis with moderate–severe pain. A placebo arm was not included because celecoxib, the reference treatment, had proven efficacy versus placebo in knee osteoarthritis, for example5 ,6; so, this was felt to be unethical and unnecessary. While Zeng et al1 agreed with this decision, they brought up some interesting points.
The original 24-week …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.